The company is largely virtual. Chief executive Bruce Schneider, the only full-time employee, is based in Pennsylvania, while many of the company’s functions are contracted out.
Omni Bio’s new headquarters is at 181 W. Boardwalk Dr. Schneider said this week that the move was made to place the company nearer to the offices of its primary investors. He said the company’s acting controller lives in Fort Collins and works out of the headquarters on a part-time basis. The company’s chief science officer, Charles Dinarello, is a professor of medicine and immunology at the University of Colorado Denver, and is leading the company’s research.
Omni Bio, which is pre-revenue, is developing a recombinant form of Alpha-1 Antitrypsin (AAT) for the treatment of a variety of inflammatory and immune-modulated diseases.
The company, which trades over the counter under the ticker symbol OMBP, in April announced a $3 million private placement funding. Schneider said Omni Bio is gearing up for a larger public offering later this year as it works to take its product to clinical testing.